Drug Trial Radar · NCT02899936
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
Last checked: Nov 19, 2026Latest source record: Dec 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23,789
Actual
Start
Jul 2016
Primary completion
Apr 27, 2017
Study completion May 31, 2018
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Case Western Reserve University; Indian Council of Medical Research
- First posted
- Sep 14, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community in 5 different countries. The objective is to acquire safety, efficacy, and acceptability data to assess the safety and acceptability of the IDA drug combination.
Conditions
- Lymphatic Filariasis
Interventions
3 drug dose - IDADrug
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
2 drug dose - DADrug
Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by modified CTCAE v4.0 scaleTime frame: within 7 days of drug administration
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Ministere de la Sante Publique et de la Population
Port-au-Prince, Haiti
Vector Control Research Centre
Puducherry, India
Universitas Indonesia
Jakarta, Indonesia
Papua New Guinea Institute for Medical Research
Madang, Papua New Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.